indan-2,2-dicarboxylic acid, dimethyl ester | 276888-00-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: indan-2,2-dicarboxylic acid, dimethyl ester
• 英文别名: 2,2-dimethyl 1,3-dihydroindene-2,2-dicarboxylate；dimethyl 1H-indene-2,2(3H)-dicarboxylate；dimethyl 1,3-dihydroindene-2,2-dicarboxylate
• CAS: 276888-00-7
• 化学式: C₁₃H₁₄O₄
• 分子量: 234.252
• InChiKey: PGPSCACBHUTBEE-UHFFFAOYSA-N

物化性质

• 沸点：
  294.7±35.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,2-Dimethyl 1,3-dihydroindene-2,2-dicarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,2-Dimethyl 1,3-dihydroindene-2,2-dicarboxylate
CAS number: 276888-00-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14O4
Molecular weight: 234.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  indan-2,2-dicarboxylic acid, dimethyl ester 在 镍 吡啶 、 lithium aluminium tetrahydride 、 氨 、 氢气 、 sodium hydride 、 lithium bromide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.5h， 生成 spiro[(1-aminocyclobutane)-3:2'-indan]-1-methylamine
  参考文献：
  名称：

  潜在的抗抑郁药显示组合的alpha（2）-肾上腺素受体拮抗剂和单胺摄取抑制剂的性质。

  摘要：

  人们认为经典的抗抑郁药通过提高大脑中的单胺（5-羟色胺和去甲肾上腺素）水平来发挥作用。通常通过抑制单胺代谢（MAO抑制剂）或阻断单胺摄取（三环类抗抑郁药和选择性5-羟色胺或去甲肾上腺素再摄取抑制剂）来完成该作用。但是，所有此类药物均存在时滞（3--6周），才能证明其强大的临床功效。此延迟可能反映了去甲肾上腺素对突触前α（2A）-肾上腺素能自发或异源受体的抑制作用，该抑制作用在长时间暴露下会逐渐下调。具有单胺摄取抑制特性的拮抗剂对突触前α（2A）-肾上腺素受体的阻断作用可能导致新的抗抑郁药具有更高的疗效和更短的时间延迟。在文献中 仅描述了两个具有这种药理学特征的分子。其中，萘哌唑（2）被选为设计4（5）-[（（3,4-二氢-2-萘基）甲基] -4,5-二氢咪唑（4a）的起点。所需的配置文件：α（2A）-肾上腺素受体拮抗剂特性和5-羟色胺/去甲肾上腺素摄取抑制。从这个原始分子，设计并合成了一系

  DOI：

  10.1021/jm001040g
• 作为产物：
  描述：

  dimethyl 2-(2-(((4-chlorobenzyl)oxy)methyl)benzylidene)malonate 在 scandium tris(trifluoromethanesulfonate) 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以83%的产率得到indan-2,2-dicarboxylic acid, dimethyl ester
  参考文献：
  名称：

  基于[1,6]-氢化物转移/环化过程的七/五元环的发散访问

  摘要：

  我们已经实现了基于 [1,6]-氢化物移位/环化过程从带有邻烷氧基甲基的亚苄基丙二酸酯获得七/五元环的不同途径。Yb(OTf) 3选择性地提供苯并氧杂环庚烷（具有七元环），而使用Sc(OTf) 3时，茚满（具有五元环）是主要产物。

  DOI：

  10.1021/acs.orglett.1c03523

文献信息

• Ruthenium(II)-Catalyzed Selective Intramolecular [2 + 2 + 2] Alkyne Cyclotrimerizations
  作者：Yoshihiko Yamamoto、Takayasu Arakawa、Ryuji Ogawa、Kenji Itoh

  DOI：10.1021/ja0358697

  日期：2003.10.1

  containing functional groups such as ester, ketone, nitrile, amine, alcohol, sulfide, etc. can be used for the present ruthenium catalysis. The most significant advantage of this protocol is that the cycloaddition of unsymmetrical 1,6-diynes with one internal alkyne moiety regioselectively gave rise to meta-substituted products with excellent regioselectivity. Completely intramolecular alkyne cyclotrimerization

  在催化量的 Cp*RuCl(cod) 存在下，1,6-二炔在环境温度下与单炔进行化学选择性反应，以良好的产率得到所需的双环苯衍生物。多种含有官能团如酯、酮、腈、胺、醇、硫化物等的二炔和单炔可用于本发明的钌催化。该协议最显着的优点是不对称 1,6-二炔与一个内部炔烃部分的环加成区域选择性产生了具有优异区域选择性的间位取代产品。完全分子内炔烃环三聚也使用三炔底物完成，以获得与 5-7 元环稠合的三环芳族化合物。与这些环三聚反应相关的 ruthenabicycle 复合物是由 Cp*RuCl(cod) 和具有苯基端基的 1,6-二炔合成的，其结构由 X 射线分析明确确定。这种钌环中间体的中间体通过它与乙炔的反应得到了进一步证实，产生了预期的环加合物。环三聚机制的密度泛函研究表明，环三聚通过氧化环化进行，产生一个钌环中间体，随后由合成的钌环与炔烃的正式 [2 + 2] 环加成引发的炔烃插入。这种钌
• Highly chemo- and regio-selective [2 + 2 + 2] cycloaddition of unsymmetrical 1,6-diynes with terminal alkynes catalyzed by Cp*Ru(cod)Cl under mild conditions
  作者：Yoshihiko Yamamoto、Ryuji Ogawa、Kenji Itoh

  DOI：10.1039/b000466i

  日期：——

  Ru(II)-catalyzed cycloaddition of unsymmetrical 1,6-diynes gives the desired cycloadducts in high yields with a regioselectivity meta∶ortho = 88∶12–98∶2.

  Ru(II) 催化的不对称 1,6-二炔的环加成以高产率得到所需的环加合物，区域选择性间位：邻位 = 88:12–98:2。
• Copper-Catalyzed Cross-Coupling of Benzylic C–H Bonds and Azoles with Controlled <i>N</i>-Site Selectivity
  作者：Si-Jie Chen、Dung L. Golden、Shane W. Krska、Shannon S. Stahl

  DOI：10.1021/jacs.1c07117

  日期：2021.9.15

  ambident reactivity of many azoles, however, presents significant selectivity challenges. Here, we report a copper-catalyzed method that achieves site-selective cross-coupling of pyrazoles and other N–H heterocycles with substrates bearing (hetero)benzylic C–H bonds. Excellent N-site selectivity is achieved, with the preferred site controlled by the identity of co-catalytic additives. This cross-coupling

  唑类是药物化学中的重要基序，通过直接 N-H/C-H 偶联来阐述其结构可能在药物发现中具有广泛的用途。然而，许多唑类的环境反应性提出了重大的选择性挑战。在这里，我们报道了一种铜催化方法，该方法实现了吡唑和其他 N-H 杂环与带有（杂）苄基 C-H 键的底物的位点选择性交叉偶联。实现了优异的N位点选择性，优选位点由助催化添加剂的特性控制。这种交叉偶联策略具有广泛的 N-H 杂环和苄基 C-H 偶联伙伴的范围，使得该方法能够应用于复杂的分子合成和药物化学。
• BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS
  申请人：McCormick Kevin D.

  公开号：US20110251207A1

  公开（公告）日：2011-10-13

  In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的双芳基螺环氨氧嗪类似物，作为α2C肾上腺素受体激动剂的调节剂，制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的制剂的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一种或多种疾病的方法。
• BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20130045914A1

  公开（公告）日：2013-02-21

  In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的双芳基螺环氨氧嗪类似物，作为α2C肾上腺素受体激动剂的调节剂，制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一种或多种疾病的方法。